Burnett Patrick sold $395K of ARQT

Burnett Patrick (See Remarks) sold 15,000 shares of Arcutis Biotherapeutics, Inc. (ARQT) at an average of $26.33 ($26.08–$26.52, $0.39M total) across 2 trades over 2026-08-11 to 2026-08-12.

Original reporting
SEC EDGAR · Burnett Patrick
Published Aug 14, 2026, 12:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 12:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The newest disclosed fact is the officer’s open-market sale details and post-transaction holdings. The text does not include any new company guidance, trial results, regulatory actions, or deal activity.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no fundamental catalyst in the filing text.

03

What to watch

No context is provided on total compensation, tax obligations, or whether other insiders sold/bought around the same time, limiting inference from the transaction alone.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-13 after trades on 2026-08-11 to 2026-08-12

Background

The article is a SEC Form 4 insider transaction disclosure for Arcutis Biotherapeutics, Inc. (ARQT).

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Arcutis Biotherapeutics Form 4 shows officer Burnett Patrick sold 15,000 shares in open-market trades at about $26.08 to $26.52.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated and no accompanying operational or guidance change in the text.

Market effects

Minimal. Insider selling in a single biotech name does not establish a sector-wide signal from the provided text.

None indicated.

None indicated.

Counterpoint

The sale could be driven by personal liquidity needs rather than negative expectations, especially since the trades are spread across two days.

Key entities

  • Arcutis Biotherapeutics, Inc.

    US-listed biotech company subject of the Form 4 insider sale disclosure.

  • Burnett Patrick

    Officer who sold 15,000 ARQT shares across two open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.